Why the study?
Does anticoagulation monitoring using anti-factor Xa activity, ACT, or aPTT prevent thromboembolic and hemorrhagic events in patients receiving ECMO support?
Does anticoagulation monitoring using anti-factor Xa activity, ACT, or aPTT prevent thromboembolic and hemorrhagic events in patients receiving ECMO support?
Answers are grounded in this paper and cite their sources.
While anti-factor Xa monitoring shows moderate correlation with heparin infusion rates and potential in preventing thrombosis during ECMO, current time-guided monitoring tools have significant limitations and require combination with clinical judgment to prevent bleeding.
Should we rely on anticoagulation monitoring in ECMO patients or simply flip a coin? The increasing use of anti-factor Xa activity to monitor the effect of UFH appears appropriate, given its moderate correlation with the UFH infusion rates, and it may play a role in preventing thromboembolic events. However, to avoid bleeding complications, more sophisticated tools, and careful clinical decision-making remain essential.
No takes yet. Share an insight, caveat, or question.
Rajšić et al. (2024) conducted an editorial in Patients receiving extracorporeal membrane oxygenation (ECMO) support for refractory cardiac or respiratory failure. Anti-factor Xa activity monitoring for unfractionated heparin (UFH) vs. Time-guided anticoagulation monitoring tools (activated clotting time [ACT] and activated partial thromboplastin time [aPTT]) was evaluated on Hemorrhagic and thromboembolic events, and correlation with unfractionated heparin (UFH) infusion rates.
Synapse has enriched 10 related papers. Consider them for comparative context: